JP6851998B2 - 多相組成物 - Google Patents

多相組成物 Download PDF

Info

Publication number
JP6851998B2
JP6851998B2 JP2017568160A JP2017568160A JP6851998B2 JP 6851998 B2 JP6851998 B2 JP 6851998B2 JP 2017568160 A JP2017568160 A JP 2017568160A JP 2017568160 A JP2017568160 A JP 2017568160A JP 6851998 B2 JP6851998 B2 JP 6851998B2
Authority
JP
Japan
Prior art keywords
variable
composition
skin
colloidal particles
aoi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017568160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522876A (ja
JP2018522876A5 (enExample
Inventor
ウルフ ガーラウェイ、リチャード
ウルフ ガーラウェイ、リチャード
ヘンリー、ウィリアム
Original Assignee
シクエスサム テクノロジー ホールディングス リミテッド
シクエスサム テクノロジー ホールディングス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1511469.7A external-priority patent/GB201511469D0/en
Priority claimed from GBGB1511478.8A external-priority patent/GB201511478D0/en
Application filed by シクエスサム テクノロジー ホールディングス リミテッド, シクエスサム テクノロジー ホールディングス リミテッド filed Critical シクエスサム テクノロジー ホールディングス リミテッド
Publication of JP2018522876A publication Critical patent/JP2018522876A/ja
Publication of JP2018522876A5 publication Critical patent/JP2018522876A5/ja
Application granted granted Critical
Publication of JP6851998B2 publication Critical patent/JP6851998B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017568160A 2015-06-30 2016-06-30 多相組成物 Active JP6851998B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1511469.7A GB201511469D0 (en) 2015-06-30 2015-06-30 Compositions
GB1511469.7 2015-06-30
GB1511478.8 2015-06-30
GBGB1511478.8A GB201511478D0 (en) 2015-06-30 2015-06-30 Blended formulations
PCT/EP2016/065425 WO2017001625A1 (en) 2015-06-30 2016-06-30 Multiphasic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021038221A Division JP2021091730A (ja) 2015-06-30 2021-03-10 多相組成物

Publications (3)

Publication Number Publication Date
JP2018522876A JP2018522876A (ja) 2018-08-16
JP2018522876A5 JP2018522876A5 (enExample) 2019-07-18
JP6851998B2 true JP6851998B2 (ja) 2021-03-31

Family

ID=56292753

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017568160A Active JP6851998B2 (ja) 2015-06-30 2016-06-30 多相組成物
JP2021038221A Pending JP2021091730A (ja) 2015-06-30 2021-03-10 多相組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021038221A Pending JP2021091730A (ja) 2015-06-30 2021-03-10 多相組成物

Country Status (14)

Country Link
US (5) US20190167588A1 (enExample)
EP (3) EP3316856B1 (enExample)
JP (2) JP6851998B2 (enExample)
CA (2) CA3026484A1 (enExample)
DK (2) DK3316856T3 (enExample)
EA (2) EA038613B1 (enExample)
ES (2) ES2879383T3 (enExample)
HR (2) HRP20210903T1 (enExample)
HU (2) HUE056161T2 (enExample)
LT (2) LT3316857T (enExample)
MX (4) MX382034B (enExample)
PL (2) PL3316856T3 (enExample)
PT (2) PT3316857T (enExample)
WO (2) WO2017001625A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3316857T (lt) 2015-06-30 2021-11-25 Sequessome Technology Holdings Limited Daugiafazės kompozicijos
EP3411012A4 (en) 2016-02-04 2019-08-28 Alastin Skincare, Inc. COMPOSITIONS AND METHODS FOR INVASIVE AND NON-INVASIVE PROCEDURAL SKIN CARE
WO2019028275A1 (en) 2017-08-03 2019-02-07 ALASTIN Skincare, Inc. COMPOSITIONS AND METHODS FOR IMPROVING LAXITY OF THE SKIN AND BODY CONTOUR
JP2020534285A (ja) 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 投与および処置の方法
WO2020028694A1 (en) 2018-08-02 2020-02-06 ALASTIN Skincare, Inc. Liposomal compositions and methods of use
JP2025099708A (ja) * 2023-12-22 2025-07-03 小林製薬株式会社 外用組成物

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372296A (en) 1980-11-26 1983-02-08 Fahim Mostafa S Treatment of acne and skin disorders and compositions therefor
JPS60136511A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 高尿酸血症治療剤
WO1987001938A1 (en) 1985-09-27 1987-04-09 The Regents Of The University Of California Liposome transdermal drug delivery system
JPS6295134A (ja) 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk リポソ−ムの製造法
US5015483A (en) 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5498607A (en) 1990-07-30 1996-03-12 University Of Miami Treatment for hypercholesterolemia
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2067754C (en) 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
ATE158175T1 (de) 1992-07-08 1997-10-15 Dianorm G Maierhofer Gmbh Liposomen, verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels
FR2714382B1 (fr) 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
FR2714596B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition cosmétique pour le traitement simultané des couches superficielles et profondes de la peau, son utilisation.
WO1996014083A1 (de) 1994-11-04 1996-05-17 Polymun Scientific Immunbiologische Forschung Gmbh Applikation von sod in liposomen
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5902604A (en) 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
FR2767691B1 (fr) 1997-08-27 2000-02-18 Oreal Utilisation d'une dispersion a base de vehicules lipidiques comme composition anti-inflammatoire
IL122084A (en) 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
TR200001393T2 (tr) 1997-11-19 2000-10-23 Schering Aktiengesellschaft Azelain asitli terkip.
US6165997A (en) 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
CA2283574A1 (en) 1998-01-16 1999-07-22 Color Access, Inc. Stabilized whitening compositions and method of preparing same
MXPA01002149A (es) 1998-09-01 2003-03-27 Idea Ag Transporte electricamente controlado de penetrantes cargados a traves de barreras.
NZ332905A (en) 1998-11-19 2000-12-22 Immuno Lab Ltd Transdermal pharmaceutical composition comprising liposomal bee venom
ES2226203T3 (es) 1998-12-23 2005-03-16 Idea Ag Formulacion mejorada para aplicacion topica no invasiva.
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
GB9902527D0 (en) * 1999-02-04 1999-03-24 Phares Pharm Res Nv Compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
US6248728B1 (en) 2000-03-10 2001-06-19 Kansas State University Research Foundation Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol
US6191121B1 (en) 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
WO2001076555A2 (en) 2000-04-12 2001-10-18 Liplasome Pharma A/S Lipid-based drug delivery systems for topical application
TWI281407B (en) 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
WO2002062316A1 (de) 2001-02-08 2002-08-15 Vectron Therapeutics Ag Invasomen zur therapie von erkrankungen, ihre herstellung und verwendung
EA200301200A1 (ru) 2001-05-31 2004-06-24 Фармация Корпорейшн Проникающая через кожу композиция селективного ингибитора циклооксигеназы-2
JP2004535434A (ja) 2001-06-25 2004-11-25 デピユイ 関節炎にかかった関節の処置のためのグリコサミノグリカン類のリポソームカプセル化
CA2368656A1 (en) 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
AU2003233396B2 (en) 2002-03-13 2007-05-24 Thomas Skold Water-based delivery systems
EP1496887B1 (en) * 2002-04-22 2016-08-03 The Procter & Gamble Company Personal care compositions comprising a zinc containing material in an aqueous surfactant composition
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
CN1470234A (zh) * 2002-07-23 2004-01-28 吴翠栓 皮肤用辣椒碱脂质体制剂
JP2004131432A (ja) 2002-10-11 2004-04-30 Kumamoto Technology & Industry Foundation 悪性腫瘍抑制剤
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
WO2004032900A1 (en) 2002-10-11 2004-04-22 Idea Ag Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
WO2004098524A2 (en) 2003-05-02 2004-11-18 Aronex Pharmaceuticals, Inc. Lipid platinum complexes and methods of use thereof
EP1514539A3 (en) * 2003-05-14 2005-05-04 Signal Investment & Management Co. Micro-encapsulated topical analgesic for pain relief and sleeve comprising it
MXPA06000805A (es) 2003-07-21 2006-04-18 Vasogen Ireland Ltd Liposomas que contienen grupos de glicerol fosfato para tratar una condicion inflamatoria aguda.
JP2005179313A (ja) 2003-12-24 2005-07-07 Shu Uemura:Kk 皮膚化粧料用基剤の製造方法および皮膚化粧料
US7476432B2 (en) 2004-05-28 2009-01-13 Tecton Products Phosphorescent pultrusion
EP1811961A2 (en) 2004-11-12 2007-08-01 Idea Ag Extended surface aggregates in the treatment of skin conditions
WO2006086992A2 (en) 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
US20070042008A1 (en) 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
EP1933856A4 (en) 2005-08-29 2008-11-19 Sepsicure L L C METHOD OF TREATING OR PREVENTING CONDITIONS INDUCED BY GRAM POSITIVE BACTERIA
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
MX286464B (es) 2005-12-20 2011-05-10 Cenestra Llc Formulaciones de acido graso omega 3.
JP5009547B2 (ja) 2006-03-31 2012-08-22 株式会社コーセー 顔料とリポソームを含む化粧料
US7544375B1 (en) 2006-06-12 2009-06-09 Swiss Skin Repair, Inc. Composition
WO2008038292A2 (en) 2006-09-28 2008-04-03 Hadasit Medical Research Services & Development Limited Use of glycerophospholipids for joint lubrication
US20080131497A1 (en) * 2006-09-28 2008-06-05 Perkins Walter R Formulations of DNase and Methods of Use Thereof
JP4732307B2 (ja) 2006-11-20 2011-07-27 株式会社アンズコーポレーション ナノエマルション及びそれを配合した化粧料
US20100130611A1 (en) 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US9511016B2 (en) 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
ITVR20080006A1 (it) 2008-01-23 2009-07-24 David Ceretta Apparato per la realizzazione di elementi d'impasto
ES2335636B1 (es) * 2008-02-29 2011-05-11 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica de micelas mixtas.
JP2009256331A (ja) 2008-03-25 2009-11-05 Nagase Chemtex Corp 高尿酸血症、又は痛風の予防、改善、又は治療剤
US20100105139A1 (en) 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
JP2012516889A (ja) 2009-02-05 2012-07-26 ターゲッティド デリバリー テクノロジーズ リミテッド 微生物因子の増殖及び生存能力を低下させる方法
WO2010140061A2 (en) 2009-06-03 2010-12-09 John Charles Mayo Formulations for the treatment of deep tissue pain
DE112010003355T5 (de) 2009-08-21 2012-07-12 Targeted Delivery Technologies Ltd. Veskuläre Formulierungen
EP2382994A1 (en) 2010-04-26 2011-11-02 Maurizio Victor Cattaneo Ligand targeted nanocapsules for the delivery of RNAi and other agents
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
US20120045405A1 (en) 2010-08-18 2012-02-23 Gilman Miles E Under eye cream
WO2012148891A1 (en) 2011-04-29 2012-11-01 Evonik Degussa Corporation Peptide-lipid conjugates and uses thereof
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201206486D0 (en) 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
GB201208384D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
GB201208409D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
CN105473162A (zh) * 2013-07-31 2016-04-06 斯昆申技术控股有限责任公司 囊泡
LT3316857T (lt) 2015-06-30 2021-11-25 Sequessome Technology Holdings Limited Daugiafazės kompozicijos
CA3142730A1 (en) * 2019-06-04 2020-12-10 Aquavit Pharmaceuticals, Inc. Methods and compositions for microflillng the skin with hyaluronic acid using microchannel technology

Also Published As

Publication number Publication date
EA201890120A1 (ru) 2018-07-31
US20210007989A1 (en) 2021-01-14
EP3316856A1 (en) 2018-05-09
MX2018000024A (es) 2018-06-27
HUE056161T2 (hu) 2022-01-28
CA3026484A1 (en) 2017-01-05
HUE054749T2 (hu) 2021-09-28
PT3316856T (pt) 2021-07-06
DK3316857T3 (da) 2021-10-18
EP3316856B1 (en) 2021-04-07
HK1254979A1 (zh) 2019-08-02
LT3316856T (lt) 2021-07-12
US20240099976A1 (en) 2024-03-28
US20190167588A1 (en) 2019-06-06
PL3316856T3 (pl) 2021-10-25
LT3316857T (lt) 2021-11-25
DK3316856T3 (da) 2021-06-28
EP3316857B1 (en) 2021-08-04
EP3954361A1 (en) 2022-02-16
MX2021004766A (es) 2022-11-07
WO2017001625A1 (en) 2017-01-05
ES2879383T3 (es) 2021-11-22
HK1254980A1 (zh) 2019-08-02
MX381075B (es) 2025-03-12
US10744090B2 (en) 2020-08-18
WO2017001617A1 (en) 2017-01-05
PT3316857T (pt) 2021-11-03
JP2018522876A (ja) 2018-08-16
US20180311148A1 (en) 2018-11-01
MX2018000021A (es) 2018-03-15
MX382034B (es) 2025-03-13
US20210023007A1 (en) 2021-01-28
CA3026466A1 (en) 2017-01-05
EA201890119A1 (ru) 2018-07-31
HRP20211669T1 (hr) 2022-02-18
EP3316857A1 (en) 2018-05-09
US20220370353A9 (en) 2022-11-24
HRP20210903T1 (hr) 2021-09-17
ES2895910T3 (es) 2022-02-23
JP2021091730A (ja) 2021-06-17
MX2021003510A (es) 2021-05-27
PL3316857T3 (pl) 2022-01-31
EA038613B1 (ru) 2021-09-23
US11547665B2 (en) 2023-01-10
EA038208B1 (ru) 2021-07-23

Similar Documents

Publication Publication Date Title
JP2021091730A (ja) 多相組成物
KR20120129864A (ko) 소포성 제형
EP2836203B1 (en) Vesicular formulations for use in the treatment of pain or reduced mobility of a joint
US9555051B2 (en) Vesicular formulations
JP2015516453A (ja) ベシクル製剤の使用および方法
JP2015516454A (ja) ベシクル製剤のキットおよび使用
HK40058716A (en) Multiphasic compositions
HK1254979B (en) Multiphasic compositions
HK1254980B (en) Blended formulations
WO2016156470A1 (en) Vesicular formulations for use in the treatment of muscle soreness
HK1202250B (en) Vesicular formulations for use in the treatment of pain or reduced mobility of a joint
HK1202250A1 (en) Vesicular formulations for use in the treatment of pain or reduced mobility of a joint

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210310

R150 Certificate of patent or registration of utility model

Ref document number: 6851998

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250